PIPERACILLIN AND TAZOBACTAM FOR INJECTION 0.375 G
TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G · DIN 02305631 · MARCAN PHARMACEUTICALS INC
Health Canada status: APPROVED
What is PIPERACILLIN AND TAZOBACTAM FOR INJECTION?
PIPERACILLIN AND TAZOBACTAM FOR INJECTION 0.375 G contains TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G. It is listed in the Health Canada Drug Product Database under DIN 02305631, held by MARCAN PHARMACEUTICALS INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as approved, status dated 18-Oct-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PIPERACILLIN AND TAZOBACTAM FOR INJECTION used for?
Piperacillin and Tazobactam for Injection is indicated for the treatment of patients with systemic and/or local bacterial infections, caused by piperacillin resistant, piperacillin/tazobactam susceptible, ß-lactamase producing strains of the designated microorganisms in the specified conditions listed below: Intra-abdominal infections, Skin and skin structure infections, Gynecological infections, Community-acquired lower respiratory tract infections, Nosocomial pneumonia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02305631 |
|---|---|
| Brand name | PIPERACILLIN AND TAZOBACTAM FOR INJECTION |
| Generic / active ingredient | TAZOBACTAM (TAZOBACTAM SODIUM) : 0.375 G PIPERACILLIN (PIPERACILLIN SODIUM) : 3 G |
| Manufacturer | MARCAN PHARMACEUTICALS INC |
| Strength | 0.375 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01CR05 PIPERACILLIN AND BETA-LACTAMASE INHIBITOR |
| AHFS class | 08:12.16.16 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 18-Oct-2023 |
How is it stored and handled?
null
How is it supplied?
null
Is PIPERACILLIN AND BETA-LACTAMASE INHIBITOR in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for PIPERACILLIN AND TAZOBACTAM FOR INJECTION
What can be used instead?
Other Canadian products sharing ATC code J01CR05 PIPERACILLIN AND BETA-LACTAMASE INHIBITOR. 16 of 52 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 0.375 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528703 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 0.5 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02362635 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 1.5 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02330547 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 12 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02377748 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02299623 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02528673 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02402068 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 2.00 G | POWDER FOR SOLUTION | STERIMAX INC | MARKETED | DIN 02362619 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02299631 |
| PIPERACILLIN AND TAZOBACTAM FOR INJECTION | 3 G | POWDER FOR SOLUTION | AURO PHARMA INC | MARKETED | DIN 02402076 |
Who else supplies PIPERACILLIN AND BETA-LACTAMASE INHIBITOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR appears in 16 registered pack listings across 3 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ask about availability of PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.